Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors
Amr K. A. Bass, Mona S. El‐Zoghbi, El-Shimaa M. Nageeb, et al.
European Journal of Medicinal Chemistry (2020) Vol. 209, pp. 112904-112904
Closed Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?
Marta Szumilak, Anna Wiktorowska‐Owczarek, Andrzej Stańczak
Molecules (2021) Vol. 26, Iss. 9, pp. 2601-2601
Open Access | Times Cited: 121
Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids
Ankit Kumar Singh, Adarsh Kumar, Harshwardhan Singh, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 9, pp. 1071-1071
Open Access | Times Cited: 111
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 25
Anticancer benzimidazole derivatives as inhibitors of epigenetic targets: a review article
Nardin Wagih, Islam M. Abdel-Rahman, Nawal El‐Koussi, et al.
RSC Advances (2025) Vol. 15, Iss. 2, pp. 966-1010
Open Access | Times Cited: 2
Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment
Xianbo Wu, Jie Wang, Qi Liang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 151, pp. 113116-113116
Open Access | Times Cited: 41
New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization
Hamada H. H. Mohammed, Amer Ali Abd El‐Hafeez, Kareem Ebeid, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 1346-1363
Open Access | Times Cited: 39
The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods
Antonio Curcio, Roberta Rocca, Stefano Alcaro, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 620-620
Open Access | Times Cited: 14
Multitargeting HDAC Inhibitors Containing a RAS/RAF Protein Interfering Unit
Yuanjiang Wang, Jianluo Zhang, Kun Li, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 3, pp. 2066-2082
Closed Access | Times Cited: 9
Microtubule associated proteins as targets for anticancer drug development
Sadiya Khwaja, Kapil Kumar, Ranjana Das, et al.
Bioorganic Chemistry (2021) Vol. 116, pp. 105320-105320
Closed Access | Times Cited: 47
Benzimidazole hybrids as anticancer drugs: An updated review on anticancer properties, structure–activity relationship, and mechanisms of action (2019–2021)
Lian‐Shun Feng, Wen‐Qi Su, Jin‐Bo Cheng, et al.
Archiv der Pharmazie (2022) Vol. 355, Iss. 6
Closed Access | Times Cited: 35
Current trends in development of HDAC-based chemotherapeutics
Narges Cheshmazar, Maryam Hamzeh‐Mivehroud, Hojjatollah Nozad Charoudeh, et al.
Life Sciences (2022) Vol. 308, pp. 120946-120946
Closed Access | Times Cited: 35
Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities
Asmaa Ahmed, Mamdouh F. A. Mohamed, Rasha M. Allam, et al.
Bioorganic Chemistry (2022) Vol. 129, pp. 106171-106171
Closed Access | Times Cited: 29
Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Sk. Abdul Amin, Samima Khatun, Shovanlal Gayen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115594-115594
Closed Access | Times Cited: 19
Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death
Velma Ganga Reddy, Isabella S. Krider, Erick T. M. Alves, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 5999-6026
Open Access | Times Cited: 6
Design of Multi-Target drugs of HDACs and other Anti-Alzheimer related Targets: Current strategies and future prospects in Alzheimer’s diseases therapy
Osama M. Soltan, Kamal S. Abdelrahman, Amr K. A. Bass, et al.
Bioorganic Chemistry (2024) Vol. 151, pp. 107651-107651
Closed Access | Times Cited: 6
A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles
Muhamad Mustafa, Amer Ali Abd El‐Hafeez, Dalia Abdelhamid, et al.
European Journal of Medicinal Chemistry (2021) Vol. 222, pp. 113569-113569
Open Access | Times Cited: 33
Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer
Carine M. Abdelmalek, Zexi Hu, Thales Kronenberger, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 6, pp. 4616-4632
Closed Access | Times Cited: 25
An insight into therapeutic efficacy of heterocycles as histone‐modifying enzyme inhibitors that targets cancer epigenetic pathways
N. Jeelan Basha, S. M. Basavarajaiah
Chemical Biology & Drug Design (2022) Vol. 100, Iss. 5, pp. 682-698
Closed Access | Times Cited: 24
Secosteroid–quinoline hybrids as new anticancer agents
Alexey I. Ilovaisky, Alexander M. Scherbakov, Valentina M. Merkulova, et al.
The Journal of Steroid Biochemistry and Molecular Biology (2023) Vol. 228, pp. 106245-106245
Closed Access | Times Cited: 15
Recent advances in EZH2-based dual inhibitors in the treatment of cancers
Xiaojuan Yang, Xu Lu, Yang Li
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115461-115461
Closed Access | Times Cited: 13
Research progress of STAT3-based dual inhibitors for cancer therapy
Xiao-Juan Yang, Lu Xu, Yang Li, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 91, pp. 117382-117382
Closed Access | Times Cited: 13
HDAC/NAMPT dual inhibitors overcome initial drug-resistance in p53-null leukemia cells
Kairui Yue, Simin Sun, Enqiang Liu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 266, pp. 116127-116127
Closed Access | Times Cited: 5
Hydrazides as Inhibitors of Histone Deacetylases
María do Carmo Carreiras, José Marco‐Contelles
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 13512-13533
Closed Access | Times Cited: 5
Oxadiazole derivatives: Histone deacetylase inhibitors in anticancer therapy and drug discovery
Balaji Wamanrao Matore, Purusottam Banjare, Tanmoy Guria, et al.
European Journal of Medicinal Chemistry Reports (2022) Vol. 5, pp. 100058-100058
Open Access | Times Cited: 22
Novel quinoxaline derivatives as dual EGFR and COX-2 inhibitors: synthesis, molecular docking and biological evaluation as potential anticancer and anti-inflammatory agents
Eman A. Ahmed, Mamdouh F. A. Mohamed, Omran A. Omran
RSC Advances (2022) Vol. 12, Iss. 39, pp. 25204-25216
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top